Are there antibody-drug conjugates approved for HER2-Positive Breast Cancer

Antibody-Drug Conjugates (ADCs) for HER2-Positive Breast Cancer

Yes, absolutely. Antibody-drug conjugates are an important treatment option for HER2-positive breast cancer, and several are FDA-approved. Let me explain what they are and what's available.

How ADCs Work

An antibody-drug conjugate is a targeted therapy that combines two components:

• The antibody part: Targets and attaches to HER2 proteins on cancer cells
• The drug part: A chemotherapy or other toxic agent that kills the cancer cell once inside

Think of it like a guided missile—the antibody delivers the cancer-killing drug directly to HER2-positive cells, which can reduce side effects compared to traditional chemotherapy.

FDA-Approved ADCs for HER2-Positive Breast Cancer

Trastuzumab deruxtecan (Kadcyla) - This was the first ADC approved for HER2-positive breast cancer and remains widely used for both early-stage and metastatic disease.

Trastuzumab emtansine (T-DM1) - Another established ADC option that combines trastuzumab with a chemotherapy agent.

Fam-trastuzumab deruxtecan (Enhertu) - A newer ADC approved for HER2-positive metastatic breast cancer that has shown strong clinical benefit.

Clinical Context

According to NCCN Guidelines for Breast Cancer, ADCs are now considered standard options in treatment planning for HER2-positive disease, particularly for:

• Metastatic (advanced) disease
• Early-stage disease in certain high-risk situations
• Patients who have progressed on other HER2-targeted therapies

The American Cancer Society notes that these targeted therapies have improved outcomes for HER2-positive breast cancer patients significantly over the past decade.

Questions to Ask Your Oncologist

1. Which ADC, if any, is recommended for my specific situation? (stage, prior treatments, other factors)
2. How does this compare to other HER2-targeted options available to me?
3. What are the expected side effects, and how are they managed?
4. Will this be combined with other treatments?
5. What does the clinical evidence show about effectiveness for my type of HER2-positive breast cancer?

Your oncologist will determine which approach—if any—fits your individual case based on your disease stage, prior treatments, and overall health.

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.